Open AccessSequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
Author(s) -
Rizzuto Giuliana,
Leoncin Matteo,
Imbergamo Silvia,
Taurino Daniela,
Mico Maria Caterina,
Tosi Manuela,
Michelato Anna,
Buklijas Ksenija,
Spinelli Orietta,
Lussana Federico,
Lessi Federica,
Pizzi Marco,
Bonaldi Laura,
Binotto Gianni,
Rambaldi Alessandro,
Gurrieri Carmela
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5212
Subject(s) - ruxolitinib , medicine , myeloproliferative neoplasm , myeloid leukemia , janus kinase 2 , cancer research , transplantation , myeloid sarcoma , myeloid , myelofibrosis , receptor , bone marrow
The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1 ‐ JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1 ‐ JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.